Congenital Hemolytic AnemiaSymptoms, Doctors, Treatments, Advances & More
Learn About Congenital Hemolytic Anemia
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Jefferson Hematology - Honickman Center
Sophie Lanzkron is a Hematologist practicing medicine in Philadelphia, Pennsylvania. Dr. Lanzkron is rated as an Elite provider by MediFind in the treatment of Congenital Hemolytic Anemia. She is also highly rated in 11 other conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia. Dr. Lanzkron is board certified in Hematology. Dr. Lanzkron is currently accepting new patients.
Duke Adult Comprehensive Sickle Cell Center - Clinic 2N
Marilyn Telen is a Hematologist practicing medicine in Durham, North Carolina. She has been practicing medicine for over 53 years. Dr. Telen is rated as an Elite provider by MediFind in the treatment of Congenital Hemolytic Anemia. She is also highly rated in 7 other conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia. Dr. Telen is board certified in American Board Of Internal Med, Hematology/Oncology and American Board Of Internal Med, Internal Medicine.
Northwell Health Pediatric Hematology/Oncology & Stem Cell Transplant
Banu Aygun is a Pediatric Hematologist Oncology provider practicing medicine in New Hyde Park, New York. Dr. Aygun is rated as an Elite provider by MediFind in the treatment of Congenital Hemolytic Anemia. She is also highly rated in 9 other conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Splenectomy.
Summary: This is an open label, non-randomized, 2-center, phase 1/2 trial of a single infusion of sickle allele modified cluster of differentiation (CD34+) hematopoietic stem progenitor cells (HSPCs) in subjects with in subjects ≥12 years old to 35 years old severe Sickle Cell Disease (SCD). The study will evaluate the hematopoietic stem cell transplantation (HSCT) using CRISPR/Cas9 edited red blood cells ...
Summary: This is a phase 2, randomized, multiple-dose, placebo-controlled study designed to evaluate the safety, efficacy, and pharmacokinetics (PK) of CSL889 (human hemopexin) when given intravenously (IV) to adults and adolescents with sickle cell disease (SCD) experiencing vaso-occlusive crises (VOC). The main objectives of the study are to evaluate the safety and tolerability of CSL889 in study partici...